Madrigal Pharmaceuticals announces six presentations at EASL Congress

Madrigal Pharmaceuticals (MDGL) announced six presentations at the upcoming European Association for the Study of the Liver, EASL, Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial in a late-breaking oral presentation titled, “Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis.”